References
- American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med.171(4) , 388–416 (2005).
- Sopena N , SabriaM. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest127(1) , 213–219 (2005).
- Chastre J , FagonJY. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med.165(7) , 867–903 (2002).
- Leu HS , KaiserDL, MoriM, WoolsonRF, WenzelRP. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am. J. Epidemiol.129(6) , 1258–1267 (1989).
- Cook DJ , WalterSD, CookRJ et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann. Intern. Med. 129(6) , 433–440 (1998).
- Rubinstein E , KollefMH, NathwaniD. Pneumonia caused by methicillin-resistant Staphylococcus aureus.Clin. Infect. Dis.46(Suppl. 5) , S378–S385 (2008).
- Appelbaum PC . The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.Clin. Microbiol. Infect.12(Suppl. 1) , 16–23 (2006).
- Howden BP , DaviesJK, JohnsonPD, StinearTP, GraysonML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev.23(1) , 99–139 (2010).
- Mendes RE , DeshpandeLM, CastanheiraM, DipersioJ, SaubolleMA, JonesRN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother.52(6) , 2244–2246 (2008).
- Lunde CS , HartouniSR, JancJW, MammenM, HumphreyPP, BentonBM. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother.53(8) , 3375–3383 (2009).
- Higgins DL , ChangR, DebabovDV et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3) , 1127–1134 (2005).
- Krause KM , RenelliM, DifuntorumS, WuTX, DebabovDV, BentonBM. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother.52(7) , 2647–2652 (2008).
- Pace JL , KrauseK, JohnstonD et al. In vitro activity of TD-6424 against Staphylococcus aureus.Antimicrob. Agents Chemother.47(11) , 3602–3604 (2003).
- Reyes N , SkinnerR, KanigaK et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(10) , 4344–4346 (2005).
- Hegde SS , ReyesN, SkinnerR, DifuntorumS. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus.J. Antimicrob. Chemother.61(1) , 169–172 (2008).
- Barriere SL . ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol.5(12) , 1765–1773 (2010).
- Theravance, Inc. VIBATIV® (telavancin) for injection, US prescribing information. www.vibativ.com/
- Theravance, Inc. VIBATIV® (telavancin) for injection, EU prescribing information. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001240/WC500115364.pdf
- Rubinstein E , LalaniT, CoreyGR et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin. Infect. Dis. 52(1) , 31–40 (2011).
- Leonard SN , SzetoYG, ZolotarevM, GrigoryanIV. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int. J. Antimicrob. Agents37(6) , 558–561 (2011).
- Mendes RE , SaderHS, FarrellDJ, JonesRN. Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010). Diagn. Microbiol. Infect. Dis.71(1) , 93–97 (2011).
- Steed ME , VidaillacC, RybakMJ. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother.56(2) , 955–959 (2012).
- Kosowska-Shick K , ClarkC, PankuchGA et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob. Agents Chemother. 53(10) , 4217–4224 (2009).